In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus | Zendy

Amit Kaushik | Zendy; Nicole C. Ammerman | Zendy; Olumide Martins | Zendy; Nicole Parrish | Zendy; Eric L. Nuermberger | Zendy

Open Access

In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus

Author(s) -

Amit Kaushik,

Nicole C. Ammerman,

Olumide Martins,

Nicole Parrish,

Eric L. Nuermberger

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00470-19

Subject(s) - tigecycline , mycobacterium abscessus , microbiology and biotechnology , tetracycline , medicine , pharmacology , in vitro , drug resistance , antibiotics , mycobacterium , chemistry , biology , tuberculosis , pathology , biochemistry

Tigecycline is used in multidrug regimens for salvage therapy ofMycobacterium abscessus infections but is often poorly tolerated and has no oral formulation. Here, we report similarin vitro activity of two newly approved tetracycline analogs, omadacycline and eravacycline, against 28 drug-resistant clinical isolates ofM. abscessus complex.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research